General MedicationsINTRAVENOUS, SUBCUTANEOUSStandard
WEZLANA
USTEKINUMAB-AUUB
Standard Dose
90MG/ML
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Prescription
Summary
Approval overview WEZLANA is listed in Drugs@FDA under application 761285 (BLA).
Review priority: STANDARD Marketing status: Prescription Active ingredient USTEKINUMAB-AUUB Form and strength INJECTABLE;INTRAVENOUS, SUBCUTANEOUS - 90MG/ML Sponsor AMGEN INC Submission history Latest submission status date: 2025-09-25 00:00:00.
Structured Monograph
Clinical summary
Approval overview WEZLANA is listed in Drugs@FDA under application 761285 (BLA). Review priority: STANDARD Marketing status: Prescription Active ingredient USTEKINUMAB-AUUB Form and strength INJECTABLE;INTRAVENOUS, SUBCUTANEOUS - 90MG/ML Sponsor AMGEN INC Submission history Latest submission status date: 2025-09-25 00:00:00. Submission type: SUPPL.
Monitoring
- • Marketing status: Prescription
- • Review priority: STANDARD
Interaction Notes
- No interaction notes stored yet.